Ipilimumab Pharmacotherapy in Patients with Metastatic Melanoma

Immune augmentation with ipilimumab, an anti-CTLA-4 monoclonal antibody, has joined the ranks of approved immunologic agents for the treatment of metastatic melanoma. Phase III studies of ipilimumab in metastatic melanoma have demonstrated an overall survival advantage as compared to other approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeter, Joanne M., Cranmer, Lee D., Hersh, Evan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Libertas Academica 2012
Materias:
Expert Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418148/
https://www.ncbi.nlm.nih.gov/pubmed/22904648
http://dx.doi.org/10.4137/CMO.S7245

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418148/
https://www.ncbi.nlm.nih.gov/pubmed/22904648
http://dx.doi.org/10.4137/CMO.S7245

Ejemplares similares